Sanjay Shukla compensation by year
aTYR PHARMA Summary Compensation Table · all 9 fiscal years held| Component | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Salary | $402,813 | $450,000 | $450,000 | $470,250 | $510,221 | $561,243 | $561,243 | $580,887 | $638,977 |
| Bonus | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Stock awards | $0 | $0 | $25,860 | $0 | $0 | $229,080 | $0 | $0 | $0 |
| Option awards | $1,620,279 | $780,000 | $82,400 | $381,811 | $1,076,297 | $1,386,876 | $532,341 | $641,760 | $2,595,200 |
| Non-equity incentive | $131,625 | $140,549 | $95,625 | $223,369 | $293,377 | $224,500 | $196,435 | $246,877 | $210,862 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| All other | $9,840 | $9,916 | $10,076 | $8,427 | $12,813 | $9,736 | $10,506 | $10,998 | $11,214 |
| Total | $2,164,557 | $1,380,465 | $663,961 | $1,083,857 | $1,892,708 | $2,411,435 | $1,300,525 | $1,480,522 | $3,456,253 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: aTYR PHARMA INC DEF 14A filed March 26, 2026, accession 0001339970-26-000021, and prior-year filings. Open the filing on EDGAR.
How this page was built: the aTYR PHARMA INC filed document, accession 0001339970-26-000021. Every figure is read from that document and cited to the page and table it appears in. Filed March 26, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 10,375 | $8,125 | — |
| Option | 3,458 | — | $5.52 |
| Option | 53,779 | — | $2.81 |
| Option | 98,028 | — | $2.20 |
| Option | 312,500 | — | $1.50 |
| Option | 770,834 | — | $3.74 |
Per the Outstanding Equity Awards at Fiscal Year-End table in aTYR PHARMA INC's FY2025 proxy; value at the fiscal year-end close, as the company printed it.
aTYR PHARMA’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Sanjay Shukla · this page | President and CEO | $3,456,253 |
| Jill Broadfoot | Chief Financial Officer | $1,309,913 |
| Nancy Denyes | General Counsel | $1,284,841 |
Board service
aTYR PHARMA board · FY2024–FY2025How this board is paid
Company policy: aTYR PHARMA pays directors a $40,000 cash retainer. As stated in aTYR PHARMA's FY2025 proxy.
The full aTYR PHARMA compensation record
free company briefThis page is one person within aTYR PHARMA's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the aTYR PHARMA proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order aTYR PHARMA's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are aTYR PHARMA's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order ATYR
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.